The acquisition is subject to regulatory approvals and is expected to close during the second quarter of 2011.
The financial terms of the agreement were not disclosed.
Based in Ann Arbor, Michigan, Accuri is a provider of flow cytometers to the life sciences research community.
Pete Shagory, a partner of BVP, said Accuri is leading a paradigm shift in the research flow cytometry market with its technology and BVP is proud to have played a role in supporting the company through its development and early commercialization.
"We are also pleased to provide an attractive return to BVP II investors, and this exit further reinforces our commitment to investing in the life sciences sector," Shagory said.
BVP led the Series B financing round for Accuri in May 2007 and participated in subsequent financing rounds while also recruiting additional institutional investors to the company.
The announced sale of Accuri is the group’s third announced healthcare exit of the year.
Earlier this year, Baird Private Equity completed the sale of BVP portfolio company Interlace Medical to Hologic. Baird Private Equity also recently announced a definitive agreement to sell Campbell Alliance, a portfolio company of US-based buyout fund Baird Capital Partners, to inVentiv Health.
